BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 18555033)

  • 1. The value of dual time point (18)F-FDG PET imaging for the differentiation between malignant and benign lesions.
    Lan XL; Zhang YX; Wu ZJ; Jia Q; Wei H; Gao ZR
    Clin Radiol; 2008 Jul; 63(7):756-64. PubMed ID: 18555033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential diagnosis between (18)F-FDG-avid metastatic lymph nodes in non-small cell lung cancer and benign nodes on dual-time point PET/CT scan.
    Suga K; Kawakami Y; Hiyama A; Sugi K; Okabe K; Matsumoto T; Ueda K; Tanaka N; Matsunaga N
    Ann Nucl Med; 2009 Aug; 23(6):523-31. PubMed ID: 19444550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual-time point 18F-FDG PET/CT scan for differentiation between 18F-FDG-avid non-small cell lung cancer and benign lesions.
    Suga K; Kawakami Y; Hiyama A; Sugi K; Okabe K; Matsumoto T; Ueda K; Tanaka N; Matsunaga N
    Ann Nucl Med; 2009 Jul; 23(5):427-35. PubMed ID: 19437097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual time point FDG-PET/CT imaging... Potential tool for diagnosis of breast cancer.
    Zytoon AA; Murakami K; El-Kholy MR; El-Shorbagy E
    Clin Radiol; 2008 Nov; 63(11):1213-27. PubMed ID: 18929039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of 18F-FDG PET/CT in the evaluation of Ascites of Undetermined Origin.
    Zhang M; Jiang X; Zhang M; Xu H; Zhai G; Li B
    J Nucl Med; 2009 Apr; 50(4):506-12. PubMed ID: 19289438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accuracy of early and delayed FDG PET-CT and of contrast-enhanced CT in the evaluation of lung nodules: a preliminary study on 30 patients.
    Schillaci O; Travascio L; Bolacchi F; Calabria F; Bruni C; Cicciò C; Guazzaroni M; Orlacchio A; Simonetti G
    Radiol Med; 2009 Sep; 114(6):890-906. PubMed ID: 19579015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDG uptake in brown adipose tissue-a brief report on brown fat with FDG uptake mechanisms and quantitative analysis using dual-time-point FDG PET/CT.
    Esen Akkas B; Gökaslan D; Güner L; Ilgin Karabacak N
    Rev Esp Med Nucl; 2011; 30(1):14-8. PubMed ID: 20702004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differentiation of FDG-avid loco-regional recurrent and compromised benign lesions after surgery for breast cancer with dual-time point F-18-fluorodeoxy-glucose PET/CT scan.
    Suga K; Kawakami Y; Hiyama A; Matsunaga N
    Ann Nucl Med; 2009 Jun; 23(4):399-407. PubMed ID: 19452249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET.
    Kwee SA; Wei H; Sesterhenn I; Yun D; Coel MN
    J Nucl Med; 2006 Feb; 47(2):262-9. PubMed ID: 16455632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor metabolism measured by partial volume corrected standardized uptake value varies considerably in primary and metastatic sites in patients with lung cancer. A new observation.
    Bural G; Torigian DA; Houseni M; Basu S; Srinivas S; Alavi A
    Hell J Nucl Med; 2009; 12(3):218-22. PubMed ID: 19936331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temporal profile of fluorodeoxyglucose uptake in malignant lesions and normal organs over extended time periods in patients with lung carcinoma: implications for its utilization in assessing malignant lesions.
    Basu S; Kung J; Houseni M; Zhuang H; Tidmarsh GF; Alavi A
    Q J Nucl Med Mol Imaging; 2009 Feb; 53(1):9-19. PubMed ID: 18337683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Narrow time-window dual-point 18F-FDG PET for the diagnosis of thoracic malignancy.
    Conrad GR; Sinha P
    Nucl Med Commun; 2003 Nov; 24(11):1129-37. PubMed ID: 14569166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography in differential diagnosis of benign and malignant intraductal papillary-mucinous neoplasm of the pancreas.
    Tomimaru Y; Takeda Y; Tatsumi M; Kim T; Kobayashi S; Marubashi S; Eguchi H; Tanemura M; Kitagawa T; Nagano H; Umeshita K; Wakasa K; Doki Y; Mori M
    Oncol Rep; 2010 Sep; 24(3):613-20. PubMed ID: 20664965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differentiation between malignant and benign pathologic fractures with F-18-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography.
    Shin DS; Shon OJ; Byun SJ; Choi JH; Chun KA; Cho IH
    Skeletal Radiol; 2008 May; 37(5):415-21. PubMed ID: 18309481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual-time point PET/CT with F-18 FDG for the differentiation of malignant and benign bone lesions.
    Tian R; Su M; Tian Y; Li F; Li L; Kuang A; Zeng J
    Skeletal Radiol; 2009 May; 38(5):451-8. PubMed ID: 19205695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accuracy of PET for diagnosis of solid pulmonary lesions with 18F-FDG uptake below the standardized uptake value of 2.5.
    Hashimoto Y; Tsujikawa T; Kondo C; Maki M; Momose M; Nagai A; Ohnuki T; Nishikawa T; Kusakabe K
    J Nucl Med; 2006 Mar; 47(3):426-31. PubMed ID: 16513611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential of dual-time-point imaging to improve breast cancer diagnosis with (18)F-FDG PET.
    Kumar R; Loving VA; Chauhan A; Zhuang H; Mitchell S; Alavi A
    J Nucl Med; 2005 Nov; 46(11):1819-24. PubMed ID: 16269595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved discrimination of benign and malignant lesions on FDG PET/CT, using comparative activity ratios to brain, basal ganglia, or cerebellum.
    Britz-Cunningham SH; Millstine JW; Gerbaudo VH
    Clin Nucl Med; 2008 Oct; 33(10):681-7. PubMed ID: 18806567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The application of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer].
    Xu HF; Liu Y; Zhang JH; Zhou RS; Zhou FH; Yuan MH
    Zhonghua Jie He He Hu Xi Za Zhi; 2005 Feb; 28(2):108-11. PubMed ID: 15854393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18F-FDOPA PET and PET/CT accurately localize pheochromocytomas.
    Imani F; Agopian VG; Auerbach MS; Walter MA; Imani F; Benz MR; Dumont RA; Lai CK; Czernin JG; Yeh MW
    J Nucl Med; 2009 Apr; 50(4):513-9. PubMed ID: 19289420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.